Capricor Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-11.0M | $-9.8M | $-762.1K | $-6.4M | $-7.4M | $-7.8M | $-7.7M | $-6.4M |
| Depreciation & Amortization | $356.9K | $331.4K | $307.6K | $276.5K | $254.7K | $230.1K | $191.6K | $137.0K |
| Depreciation | $356.9K | $331.4K | $307.6K | $276.5K | $254.7K | $230.1K | $191.6K | $137.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $2.2M | $3.3M | $1.9M | $1.7M | $1.6M | $2.2M | $1.1M | $1.1M |
| Net Cash from Operating Activities | $-12.3M | $-1.3M | $-11.6M | $-8.8M | $-9.4M | $4.2M | $-6.9M | $-5.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $60.3K | $608.6K | $558.6K | $269.5K | $135.9K | $347.7K | $694.0K | $557.6K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $14.7M | $-9.5M | $-5.9M | $7.7M | $6.5M | $-3.2M | $5.1M | $-4.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $2.1M | $2.3M | $23.2M | $221.1K | $2.2M | $3.9K | $2.9M | $1.9M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-12.3M | $-1.9M | $-12.2M | $-9.1M | $-9.6M | $3.9M | $-7.6M | $-6.2M |